

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

SECTION 1. IDENTIFICATION

Product name : Levamisole / Oxfendazole Formulation

Other means of identification : Scanda (A007130)

Manufacturer or supplier's details

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 5

Reproductive toxicity : Category 1B

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.
H360FD May damage fertility. May damage the unborn child.
H400 Very toxic to aquatic life.
H411 Toxic to aquatic life with long lasting effects.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

Precautionary Statements

Prevention:

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P312 Call a POISON CENTER/ doctor if you feel unwell.
P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Levamisole hydrochloride	16595-80-5	>= 5 < 10
oxfendazole	53716-50-0	>= 2,5 < 5
Polyethylene glycol stearate	9004-99-3	>= 1 < 5
Citric acid	77-92-9	>= 1 < 5

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.

In case of eye contact : Thoroughly clean shoes before reuse.
Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.

Most important symptoms : May be harmful if swallowed.

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

and effects, both acute and delayed	May damage fertility. May damage the unborn child.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
Methods and materials for containment and cleaning up	: Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable

Levamisole / Oxfendazole FormulationVersion
4.0Revision Date:
14.04.2025SDS Number:
10808162-00007Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m ³ (OEB 3)	Internal
	Further information: Skin			
oxfendazole	53716-50-0	TWA	40 µg/m ³ (OEB 3)	Internal
		Wipe limit	400 µg/100 cm ²	Internal
Polyethylene glycol stearate	9004-99-3	CMP	10 mg/m ³	AR OEL
	Further information: A4 - Not classifiable as a human carcinogen			
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH
--	--	----------------------------------------------	---------------------	-------

Engineering measures	<ul style="list-style-type: none">Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.
Personal protective equipment	
Respiratory protection	<ul style="list-style-type: none">If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	
Hand protection	<ul style="list-style-type: none">Particulates type
Material	<ul style="list-style-type: none">Chemical-resistant gloves
Remarks	<ul style="list-style-type: none">Consider double gloving.
Eye protection	<ul style="list-style-type: none">Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	<ul style="list-style-type: none">Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	<ul style="list-style-type: none">If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.When using do not eat, drink or smoke.Wash contaminated clothing before re-use.The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: Aqueous solution
Color	: No data available

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available
Relative vapor density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics	
Particle size	: Not applicable

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 2.250 mg/kg
Method: Calculation method

Components:**Levamisole hydrochloride:**

Acute oral toxicity : LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

oxfendazole:

Acute oral toxicity : LD50 (Rat): > 6.000 mg/kg
LD50 (Dog): 1.600 mg/kg
LD50 (sheep): 250 mg/kg

Polyethylene glycol stearate:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5.400 mg/kg

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

||| Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Levamisole hydrochloride:**

||| Remarks : No data available

oxfendazole:

||| Species : Rabbit
||| Result : No skin irritation

Polyethylene glycol stearate:

||| Species : Rabbit
||| Method : Draize Test
||| Result : No skin irritation

Citric acid:

||| Species : Rabbit
||| Method : OECD Test Guideline 404
||| Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Levamisole hydrochloride:**

||| Remarks : No data available

oxfendazole:

||| Species : Rabbit
||| Result : No eye irritation

Polyethylene glycol stearate:

||| Species : Rabbit
||| Result : No eye irritation
||| Method : Draize Test

Citric acid:

||| Species : Rabbit
||| Result : Irritation to eyes, reversing within 21 days
||| Method : OECD Test Guideline 405

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Levamisole hydrochloride:**

||| Remarks : No data available

Polyethylene glycol stearate:

||| Test Type : Open epicutaneous test
||| Routes of exposure : Skin contact
||| Species : Guinea pig
||| Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Levamisole hydrochloride:**

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
||| Result: negative

||| Test Type: Chromosome aberration test in vitro
||| Result: negative

oxfendazole:

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
||| Result: negative

||| Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow
||| cytogenetic test, chromosomal analysis)
||| Species: Mouse
||| Application Route: Oral
||| Result: positive

Polyethylene glycol stearate:

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
||| Result: negative

Citric acid:

||| Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
||| Result: negative

||| Test Type: in vitro micronucleus test
||| Result: positive

Levamisole / Oxfendazole FormulationVersion
4.0Revision Date:
14.04.2025SDS Number:
10808162-00007Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo

: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	80 mg/kg body weight
Remarks	:	No significant adverse effects were reported

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

oxfendazole:

Species	:	Rat
Application Route	:	Oral
Exposure time	:	1 Years
Symptoms	:	No adverse effects.
Target Organs	:	Liver

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
Symptoms	:	No adverse effects.
Target Organs	:	Liver

Reproductive toxicity

May damage fertility. May damage the unborn child.

Components:**Levamisole hydrochloride:**

Effects on fertility	:	Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported
----------------------	---	------------------------------------------------------------------------------------------------------------------------------------------------------------

Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Oral
------------------------------	---	--------------------------------------------------------------------------------

Levamisole / Oxfendazole Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 10808162-00007	Date of last issue: 06.07.2024 Date of first issue: 05.07.2022
----------------	------------------------------	-------------------------------	-------------------------------------------------------------------

		Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity.
		Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity.
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on development, based on animal experiments.
oxfendazole:		
Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: NOAEL: 17 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
		Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Fertility: NOAEL: 0,9 mg/kg body weight Target Organs: Liver Result: No effects on fertility.
		Test Type: Fertility Species: Mouse Application Route: Oral Duration of Single Treatment: 1 Months Fertility: NOAEL: 750 mg/kg body weight Target Organs: Testes Result: Effects on fertility.
Effects on fetal development	:	Test Type: Embryo-fetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Fetal effects.
		Test Type: Embryo-fetal development Species: Rat Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: positive, Embryo-fetal toxicity.
		Test Type: Embryo-fetal development Species: Mouse Application Route: Oral Developmental Toxicity: NOAEL: 108 mg/kg body weight Result: positive, Embryo-fetal toxicity., Fetal abnormalities.
		Test Type: Embryo-fetal development Species: Rabbit

Levamisole / Oxfendazole Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 10808162-00007	Date of last issue: 06.07.2024 Date of first issue: 05.07.2022
----------------	------------------------------	-------------------------------	-------------------------------------------------------------------

		Application Route: Oral Developmental Toxicity: NOAEL: 0,625 mg/kg body weight
Reproductive toxicity - Assessment	:	Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.
Citric acid: Effects on fetal development	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative

STOT-single exposure

Not classified based on available information.

Components:**Citric acid:**

Assessment	:	May cause respiratory irritation.
------------	---	-----------------------------------

STOT-repeated exposure

Not classified based on available information.

Components:**Levamisole hydrochloride:**

Target Organs Assessment	:	Blood, Testis
	:	May cause damage to organs through prolonged or repeated exposure.

oxfendazole:

Routes of exposure	:	Oral
Target Organs	:	Liver, Testis
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Levamisole hydrochloride:**

Species	:	Rat
NOAEL	:	2,5 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Testis

Species	:	Dog
LOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Target Organs	: Blood
Species	: Dog
LOAEL	: 40 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
oxfendazole:	
Species	: Rat
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Blood, Liver, Testis
Species	: Rat
NOAEL	: 3,8 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver, Testis
Species	: Mouse
NOAEL	: 750 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Target Organs	: Liver
Species	: Mouse
NOAEL	: 37,5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Liver
Species	: Dog
NOAEL	: 6 mg/kg
Application Route	: Oral
Exposure time	: 1 Months
Remarks	: No significant adverse effects were reported
Species	: Dog
NOAEL	: 11 mg/kg
Application Route	: Oral
Exposure time	: 2 Weeks
Target Organs	: Lymph nodes, thymus gland
Species	: Dog
NOAEL	: 13,5 mg/kg
Application Route	: Oral
Exposure time	: 12 Months
Target Organs	: Liver

Citric acid:

Species	: Rat
NOAEL	: 4.000 mg/kg
LOAEL	: 8.000 mg/kg

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

Application Route : Ingestion
Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Levamisole hydrochloride:

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Levamisole hydrochloride:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37,3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

oxfendazole:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): > 2,7 mg/l
Exposure time: 96 h

LC50 (Oncorhynchus mykiss (rainbow trout)): > 2,5 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,059 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

M-Factor (Acute aquatic toxicity) : 10

Toxicity to daphnia and other aquatic invertebrates (Chron- : NOEC (Daphnia magna (Water flea)): 0,023 mg/l
Exposure time: 21 d

Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

Chronic toxicity (fish) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

Polyethylene glycol stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 10.000 mg/l
Exposure time: 96 h
Method: DIN 38412

Toxicity to microorganisms : EC10 (Bacteria): > 10.000 mg/l
Exposure time: 16 h

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1.535 mg/l
Exposure time: 24 h

Persistence and degradability**Components:****oxfendazole:**

Stability in water : Hydrolysis: < 5 %(4 d)

Polyethylene glycol stearate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: > 70 %
Exposure time: 10 d
Method: OECD Test Guideline 302B

Citric acid:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

Bioaccumulative potential**Components:****oxfendazole:**

Partition coefficient: n-octanol/water : log Pow: 1,95

Citric acid:

Partition coefficient: n-octanol/water : log Pow: -1,72

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10808162-00007 Date of last issue: 06.07.2024 Date of first issue: 05.07.2022

Mobility in soil

Components:

oxfendazole:

Distribution among environmental compartments : log Koc: 3,2

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxfendazole)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(oxfendazole)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(oxfendazole)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version 4.0	Revision Date: 14.04.2025	SDS Number: 10808162-00007	Date of last issue: 06.07.2024 Date of first issue: 05.07.2022
----------------	------------------------------	-------------------------------	-------------------------------------------------------------------

Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry. : Not applicable

Control of precursors and essential chemicals for the preparation of drugs. : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 14.04.2025
Date format : dd.mm.yyyy

Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AR OEL : Argentina. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average
AR OEL / CMP : TLV (Threshold Limit Value)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with

SAFETY DATA SHEET



Levamisole / Oxfendazole Formulation

Version
4.0

Revision Date:
14.04.2025

SDS Number:
10808162-00007

Date of last issue: 06.07.2024
Date of first issue: 05.07.2022

x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8